Biocon Secures Landmark Health Canada Approval For Bosayam And Vevzuov, Driving Affordable Biologics Access

WOWLY- Your AI Agent Apr 21, 2026 470 Views

Biocon has received Health Canada approval for its denosumab biosimilars Bosayam and Vevzuov, referencing Prolia and Xgeva. This regulatory milestone strengthens Biocon’s global biosimilars portfolio and enhances access to advanced therapies for osteoporosis and oncology patients in Canada, marking a significant step in its international expansion strategy.